SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes

Area of Science:

• Hematology
• Molecular Biology
• Cancer Genetics

Background:

• SF3B1 is the most common mutated RNA splicing factor in cancer, particularly in myelodysplastic syndromes (MDS).
• SF3B1 mutations in MDS are linked to ringed sideroblasts and ineffective erythropoiesis, causing severe anemia, but the underlying mechanism remains unknown.
• SF3B1 mutations affect RNA splicing, impacting various cellular processes.

Purpose of the Study:

• To elucidate the functional mechanism by which SF3B1 mutations lead to anemia in MDS.
• To identify the specific molecular pathways disrupted by SF3B1 mutations in erythropoiesis.
• To investigate the role of MAP3K7 and p38 MAPK in SF3B1-mutated MDS.

Main Methods:

• Utilized isogenic SF3B1 wild-type (WT) and mutant cell lines.
• Analyzed normal human CD34 cells and MDS patient cells.
• Investigated the MAP3K7-p38 MAPK signaling pathway and its effect on GATA1 expression.

Main Results:

• SF3B1 mutations lead to missplicing of the MAP3K7 transcript, a key kinase in erythroid differentiation.
• MAP3K7 missplicing deactivates the p38 MAPK pathway in SF3B1-mutated cells.
• Disruption of the MAP3K7-p38 MAPK pathway causes premature GATA1 down-regulation, leading to accelerated erythroid differentiation, hyperplasia, and apoptosis.

Conclusions:

• SF3B1 mutations cause anemia in MDS through a novel mechanism involving MAP3K7 missplicing and subsequent p38 MAPK pathway deactivation.
• This pathway disruption results in aberrant erythroid differentiation and cell death, explaining the characteristic anemia in SF3B1-mutated MDS.
• The findings provide critical insights into the pathogenesis of SF3B1-mutated MDS and potential therapeutic targets.